Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 312 of 5804
-
Stem cells could save sight after chemical burns
Disease control Not yet recruitingSevere chemical burns of the eye are serious injuries that can cause intense inflammation of the ocular surface and destroy limbal epithelial stem cells, which are essential for corneal healing. These injuries may lead to severe vision loss, blindness, or even loss of the eye des…
Phase: PHASE2 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Chemo-Seeds planted in brain show promise against deadliest tumors
Disease control Not yet recruitingPart 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection. Part 1 will evaluate safety, determine the MTD of irinotecan-ChemoSeed and the RP2D (corre…
Phase: PHASE2 • Sponsor: CRISM Therapeutics LTD • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for mild stroke: catheter procedure could boost recovery
Disease control Not yet recruitingThis study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.
Phase: NA • Sponsor: Feng Gao • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could anakinra save brain tissue after a stroke? new trial aims to find out
Disease control Not yet recruitingThe investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved s…
Phase: PHASE2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New antibody combo targets tough lymphoma in early trial
Disease control Not yet recruitingThis is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists tw…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to shrink ovarian tumors before surgery
Disease control Not yet recruitingThis is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for patients with advanced high-grade serous ovarian ca…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug takes on T-DXd in breast cancer showdown
Disease control Not yet recruitingThis is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg/kg Q3W) or T-DXd (5.4 mg/kg Q3W) for 8 neoadjuvant cycles. After completing neoadjuvant treatment, patients wil…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene therapy hope for sickle cell: tiny trial tests One-Time fix
Disease control Not yet recruitingIt is a single-arm, single-center, open-label, single-dose study. A total of three subjects with severe sickle cell disease (SCD), aged 12-50 years (inclusive), are planned to receive cell infusion. After successful hematopoietic stem cell engraftment is achieved in the first sub…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could CAR T-Cells tame tough lupus? tiny trial aims to find out
Disease control Recruiting nowThe goal of this Phase I clinical trial is to evaluate the safety and tolerability of autologous CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy in adults with refractory systemic lupus erythematosus who have demonstrated inadequate response to standard-of-care imm…
Phase: PHASE1 • Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Not yet recruitingThis is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital. It evaluates the efficacy and safety of a combination regimen (liposomal irinotecan + vincristine + temozolomide ± anlotinib) in children w…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
One-Stop stroke suite could save minutes and brains
Symptom relief Not yet recruitingRationale: Acute ischemic stroke caused by large-vessel occlusion (LVO) requires rapid recanalization to minimize neurological damage, as shorter onset-to-reperfusion times are strongly associated with better clinical outcomes. Conventional management workflows, which involve sep…
Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Neck surgery aims to flush Alzheimer's proteins from the brain
Disease control Not yet recruitingOfficial Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease Purpose of the Study Researchers are conducting this study to see if a minimally invasive microsurgery, called Cervical Lymphaticovenular Anast…
Phase: PHASE1 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental cocktail aims to neutralize deadly grain fumigant poisoning
Disease control Not yet recruitingMetal phosphides are commonly utilized for safeguarding stored grains due to their desirable characteristics. They have high potency and the ability to combat different pests and produce non-toxic residues in crops . In countries like Iran, India, and Egypt, metal phosphides are…
Phase: NA • Sponsor: Sohag University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could ketamine lift depression in Parkinson's? VA launches new trial
Symptom relief Recruiting nowParkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments f…
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
AI could solve thyroid nodule mystery: new study aims to predict cancer risk
Diagnosis Recruiting nowThe prospective study aim to develop a multimodal deep learning model that integrates ultrasound images and cytological whole-slide images for more accurate malignant risk prediction of Bethesda III thyroid nodules.
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to wipe out lung cancer before surgery
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of JSKN016 combined with toripalimab and carboplatin as a neoadjuvant treatment regimen in patients with resectable stage II-III NSCLC.
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is: • Whether the efficacy and safety of QL1207H and aflibercept…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo drug strategy aims to help Crohn's patients who Don't respond fully to standard therapy
Disease control Recruiting nowThis multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with moderate-to-severe Crohn's disease who have a subopt…
Phase: PHASE4 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare fever disorder: drug targets stubborn cases
Disease control TerminatedThe purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with colchicine-resistand Familial Mediterranian Fever (FMF). The study consists of up to one month screening, to see if a patient is suitable to the study, 6 months of treatment with…
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Heart surgery for athletes: does zapping faulty signals boost or bust performance?
Disease control Recruiting nowThe relationship between exercise and atrial fibrillation (AF) seems to follow a J-shaped curve: while moderate activity reduces AF risk, both insufficient and excessive endurance exercise increase susceptibility. In athletes, standard treatments such as antiarrhythmic drugs ofte…
Phase: NA • Sponsor: University Hospital of Leuven Leuven • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC